Data Investigating KEYTRUDA (pembrolizumab), Merck's Anti-PD-1...

Data Investigating KEYTRUDA , Merck's Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting Merck , known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA , the company's anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria , in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma whose disease progressed on or after treatment with brentuximab vedotin. Complete remission was achieved in 21 percent of patients in the study.

http://ift.tt/1s69CVN